Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

1.0K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.0K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Neural Regulation01:37

Neural Regulation

43.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.9K
Dementia01:30

Dementia

633
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
633

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validated Measures of Agitation in Neurocognitive Disorders: A Systematic Review of 41 Scales and Their Alignment With International Psychogeriatric Association Criteria.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2026
Same author

Validation of the care partner stress scale in the CAN-PROTECT study.

Journal of Alzheimer's disease : JAD·2026
Same author

Mild Behavioural Impairment and Everyday Functioning in Cognitively Unimpaired Older Adults: Evidence From the CAN-PROTECT Study.

Journal of geriatric psychiatry and neurology·2026
Same author

Cross-sectional and longitudinal associations of self-perceptions of aging with physical activity in multimorbidity: The role of depressive symptoms.

Archives of gerontology and geriatrics·2026
Same author

Lifetime Exposure to Endogenous Estradiol and Markers of Dementia Risk: Associations with Later Life Cognitive, Behavioral, and Functional Complaints.

Diagnostics (Basel, Switzerland)·2026
Same author

Development and Cross-Sectional Validation of the Quality of Life and Function Five-Domain Scale (QFS-5) in Dementia-Free Community-Dwelling Older Adults.

International journal of geriatric psychiatry·2026

Related Experiment Video

Updated: Mar 6, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K

Cognitive decline in Parkinson disease.

Dag Aarsland1,2, Byron Creese1,3, Marios Politis1,4

  • 1KCL-PARCOG group, Institute of Psychiatry, Psychology &Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, UK.

Nature Reviews. Neurology
|March 4, 2017
PubMed
Summary

Mild cognitive impairment (MCI) often precedes dementia in Parkinson disease (PD). While MCI can progress, stabilization or improvement is possible, with cognitive training showing promise.

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K
Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

14.3K

Related Experiment Videos

Last Updated: Mar 6, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K
Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

14.3K

Area of Science:

  • Neuroscience
  • Neurology
  • Gerontology

Background:

  • Dementia is common in advanced Parkinson disease (PD).
  • Mild cognitive impairment (MCI) is increasingly studied as a pre-dementia stage in PD.
  • The progression of cognitive impairment in PD is variable, with potential for stabilization or reversal.

Purpose of the Study:

  • To review the mechanisms and biomarkers associated with cognitive decline in Parkinson disease.
  • To explore the predictive value of biomarkers and genetic factors for cognitive impairment in PD.
  • To assess current treatment and prevention strategies for cognitive decline in PD.

Main Methods:

  • Review of longitudinal studies on cognitive impairment in Parkinson disease.
  • Analysis of biomarker studies, including cerebrospinal fluid (CSF) analysis and advanced neuroimaging.
  • Examination of genetic risk factors associated with cognitive decline in PD.

Main Results:

  • Low CSF amyloid-β42 levels predict cognitive decline and dementia in PD, indicating comorbid Alzheimer disease (AD).
  • Genetic factors like APOE*ε4, GBA, and SCNA mutations are linked to cognitive decline in PD.
  • Cognitive enhancing medications offer some benefit for PD dementia, but prevention of MCI progression remains unproven.

Conclusions:

  • Cognitive impairment in Parkinson disease is multifactorial, involving Lewy pathology, AD-related changes, and genetic predispositions.
  • Biomarkers and genetic factors are crucial for predicting cognitive decline in PD.
  • While treatments exist for PD dementia, proactive strategies like cognitive training show potential for managing MCI in PD.